Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c

Adaptimmune Reports Second Quarter 2016 Financial Results

August 8, 2016 7:00 AM EDT

 - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -

PHILADELPHIA and OXFORD, United Kingdom, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP) (Adaptimmune or the Company), a leader in T-cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2016.

Recent Corporate and Clinical Highlights:

Received access to Priority Medicines (PRIME) regulatory support from the European Medicines Agency for NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy;Received orphan medicinal product designation for... More